Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

General Updates | TCXpress™ vs CAR-T therapy & targeting leukemia with TCR T-cells

David Apelian, MD, PhD, BlueSphere Bio, Pittsburgh, PA, comments on the main differences between the TCXpress™ platform and CAR-T therapy. In contrast to CAR-Ts, TCXpress™ uses the natural T-cell receptor (TCR), which is more potent, specific, selective, and tolerable than hybrid receptors. Moving forward, Dr Apelian gives an overview of the TCX-101 clinical program, which aims to treat patients with high-risk leukemias in the context of allogeneic hematopoietic stem cell transplantation (alloHSCT) by engineering TCR T-cells targeting minor histocompatiblity antigens (miHAs). These TCR T-cells have the potential to increase the immune pressure against the tumor, improve engraftment and greatly reduce the incidence of graft-versus-host disease (GvHD). This interview was recorded virtually.